IT

Italy

IT

Europe

Regulatory Overview

Italy is regulated by the AIFA (Agenzia Italiana del Farmaco). The country has 3 documented regulatory pathways for accessing unapproved or unlicensed medicines, covering named patient programs, compassionate use schemes, and special access arrangements.

Regulatory Authority

AIFA (Agenzia Italiana del Farmaco)

Regulatory Pathways (3)

EMA Article 83 compassionate use framework allowing access to unauthorised medicinal products for groups of patients with a chronically or seriously debilitating or life-threatening disease in Italy.

Application Form: National compassionate use form
Legal Basis: Regulated under EU Directive 2001/83/EC
Eligibility: Serious or life-threatening condition with no locally registered alternative
Reference: EMA Article 83 Compassionate Use

Italian compassionate use under Ministerial Decree of 7 September 2017 for individual patients with serious, rare or life-threatening diseases.

Application Form: AIFA Compassionate Use Application
Legal Basis: Decreto Ministeriale 7 settembre 2017
Eligibility: Serious or life-threatening condition with no locally registered alternative
Reference: AIFA DM 2017 Compassionate Use

Italian Law 648/96 allows off-label reimbursement of medicines not yet authorised in Italy for rare diseases or conditions where no valid alternative exists.

Application Form: AIFA Legge 648 Application
Legal Basis: Legge 648/96
Eligibility: Serious or life-threatening condition with no locally registered alternative
Reference: AIFA Legge 648/96 Guidance

Drugs Available (120)

DrugAccess RouteStatusLead Time
cytarabine
Ataluren
eribulin mesylate
Sucralfate
naproxen
Memantine
propranolol
Ursodeoxycholic acid
tamoxifen citrate
mitapivat
carbamazepine
ruxolitinib
mycophenolate mofetil
Epoprostenol
Fludarabine
etanercept
dapsone
mavacamten
ibuprofen
gabapentin
cyclophosphamide
bosentan
testosterone
Rho(D) immune globulin
triheptanoin
melatonin
amiodarone
Total Parenteral Nutrition
ascorbic acid
hormone replacement therapy (estrogen/progesterone)
Interferon-gamma
physical therapy and orthotic management
Retinoids (Tretinoin)
eculizumab
miglustat
lonafarnib
Betaine anhydrous
Octreotide
aspirin
oxybutynin
Valproic Acid
tocilizumab
Immunoglobulin
alpha-L-iduronidase
sirolimus
temozolomide
Carnitine
brivaracetam
folic acid
Acetazolamide
Angiotensin-Converting Enzyme Inhibitors (Enalapril)
idebenone
Multivitamin with Calcium and Vitamin D
levothyroxine sodium
botulinum toxin type A
azathioprine
L-carnitine
insulin
luspatercept
trabectedin
vosoritide
cysteamine bitartrate
rituximab
Dapagliflozin
allopurinol
Carboplatin
Topical corticosteroids
estradiol
eladocagene exuparvovec
Tolvaptan
cerliponase alfa
avalglucosidase alfa
atidarsagene autotemcel
adalimumab
tacrolimus ophthalmic
Amphotericin B liposomal
ranibizumab
diacerein
carglumic acid
calcitriol
doxorubicin
Pyridostigmine
Levetiracetam
Acitretin
prednisone
Insulin glargine
aflibercept
laronidase
Bleomycin
hydroxycobalamin
Metreleptin
acetaminophen
pregabalin
N-acetylcysteine
Pamidronate
Diosmin
ezetimibe
atorvastatin
bevacizumab
proton pump inhibitors (omeprazole)
mecasermin
celecoxib
Imiquimod
Growth Hormone
deferasirox
Tafamidis
Levodopa/Carbidopa
Lanreotide
baricitinib
Azacitidine
Zoledronic Acid
warfarin
cornstarch
disopyramide
Cisplatin
imatinib mesylate
nimodipine
Colchicine
surgical repair
Hematopoietic stem cell transplantation
IT
Italy
ISO CodeIT
RegionEurope
Regulatory AuthorityAIFA (Agenzia Italiana del Farmaco)
Pathways3 documented
Drugs Available120 drug(s)